Clinicians should be on alert for signs of medetomidine exposure and withdrawal in suspected overdose cases, public health experts recently said during a CDC webinar. Hosted by the agency’s Division of Overdose Protection, the webinar highlighted growing concerns about medetomidine’s increasing presence in the U.S. illicit drug supply – often mixed with fentanyl – and the clinical challenges of treating patients exposed to it.

More information: https://www.medpagetoday.com/publichealthpolicy/publichealth/116893